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Introduction
The ability to treat vascular disease using 
interventional approaches, as well as and 
the development of endovascular treat-
ment techniques have made the use of 
stents routine. Compared with single-ves-
sel dilatation, as in percutaneous translu-
minal angioplasty (PTA), they prevent in 
particular acute vascular recoil by provid-
ing scaffolding, thereby effectively reduc-
ing the restenosis rate [1]. Alongside per-
manent bare metal stents (BMS) of vari-
ous designs, alloys and applications, bio-
degradable polymer stents are playing an 
ever more important role. Compared with 
conventional permanent BMS, they have 
the advantage of preventing chronic for-
eign-body reactions and enabling second-
ary vascular surgery in previously stent-
ed areas.
The aim of this article is to present 
the results from an animal model fol-
lowing endovascular implantation of an 
advanced and improved biodegradable 
PLLA/P4HB stent compared with a per-
manent 316L metal stent for use in the pe-
ripheral vasculature. The effect of an oral-
ly administered statin is also investigated.
Materials and methods
PLLA/P4HB stents
The biodegradable polymer stents used in 
this study were developed, produced and 
tested in vitro at the Institute for Biomed-
ical Technology at the University Medi-
cine Rostock [2].
In brief, the stents were produced in an 
automated, PC-assisted immersion pro-
cess and cut from tiny tubes (Di = 2.2 mm, 
Da = 2.7 mm) using a CO2 laser [2]. The 
stents were made from a blend of poly(l-
lactide) and poly(4-hydroxybutyrate) 
(PLLA/P4HB). The chemical compo-
sition of their basic substance consist-
ed of 78 % PLLA (Resomer L214, Boeh-
ringer, Ingelheim, Germany) and 22 % 
P4HB (TephaFLEX, Tepha, Inc., Lexing-
ton, MA, US). . Fig. 1 shows the PLLA/
P4HB stent with its nominal dimension 
of 5.0 × 20 mm (wall thickness: 250 μm).
Metal stents
Non-biodegradable stents made from 
medical-grade stainless steel (316L) and 
coated with amorphous silicon carbide 
(Dynamic, Biotronik SE & Co. KG, Ber-
lin, Germany) with a nominal dimension 
of 5.0 × 25 mm (wall thickness: 160 μm) 
were used as controls.
Animal preparation
The experiments were approved by the 
Mecklenburg-Vorpommern Regional 
Office for Agriculture, Food Safety and 
Fisheries in accordance with the regula-
tions on animal experiments set out in §8 
par. 1 of the German Animal Welfare Act. 
The study used 10 healthy female domes-
tic swine weighing 26.1 ± 1.7 kg.
Food was withheld for at least 12 h pre-
operatively, beginning on the day prior to 
surgery; drinking water remained avail-
able at all times. The experimental ani-
mals were premedicated with azaperone 
[Stresnil, 5 mg/kg body weight (BW); 
Janssen-Cilag, Neuss, Germany), ket-
amine (40 mg/kg BW; Bela-Pharm, Vech-
ta, Germany), midazolam (Dormicum, 
0.2 mg/kg BW; Hoffmann La Roche, 
Grenzach/Wyhlen, Germany) and at-
ropine sulfate (0.01 mg/kg BW; Germa-
ny)] via intramuscular injection in the 
neck area. The animals were intubat-
ed and received volume-controlled me-
chanical ventilation (Ventilog 2, Dräger, 
Lübeck, Germany) with a 40 % oxy-
gen–1.2 Vol% isoflurane (Abbott GmbH 
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& Co KG, Wiesbaden, Germany) mix-
ture. The animals were anesthetized dur-
ing surgery with fentanyl (0.25 mg/h i.v., 
Fentanyl-Janssen, Janssen-Cilag, Neuss, 
Germany) and pancuronium (10 mg/h 
i.v., Pancuronium Hikma, Hikma Phar-
ma, Klein-Winternheim, Germany) ad-
ministered to the ear via a 20-G indwell-
ing catheter (Vasofix, Braun-Melsun-
gen AG, Germany). Fluid substitution 
was performed with Ringer’s lactate 
(Sterofundin, Braun-Melsungen AG, 
Germany). Ampicillin/sulbactam (1.5 g; 
Unacid, Pfizer, Karlsruhe, Germany) 
was administered preoperatively as a sin-
gle-shot antibiotic prophylaxis.
One group of five animals also re-
ceived 60 mg/day atorvastatin (Sortis, 
Pfizer, Germany) orally in addition to 
food, beginning 5 days prior to surgery 
and lasting until the study ended.
Stent implantation
Following surgical incision in the low-
er left quadrant of the abdomen, the left 
common iliac artery was exposed. A 6-F 
sheath (Radiofocus Introducer, Teru-
mo, Germany) was introduced by punc-
ture. After probing the target vessel, an 
8-F introducer system (Flexor Tuohy-
Borst Sidearm Introducer, Cook, Germa-
ny) was inserted over a guidewire (Rosen 
Wire, Cook, Germany). The stents were 
placed in the carotid artery under X-ray 
fluoroscopy and then balloon-expanded.
As a commercial stent-catheter sys-
tem (Dynamic 5/25/130, Biotronik SE 
& Co. KG, Berlin, Germany), the metal 
stents were rapidly inflated with a pres-
sure of 9 bar. The biodegradable PLLA/
P4HB stents were implanted using a 
5.0 × 40 mm PTA balloon catheter (Pas-
seo-35: 5/40/130, Biotronik SE & Co. KG, 
Berlin, Germany). To this end, the PLLA/
P4HB stents were mounted manually on 
the balloon catheter, predilated extracor-
poreally with 1 bar (. Fig. 2) and dilated 
in situ at the target site with a pressure of 
8 bar for 1 min. The side of the common 
carotid artery (CCA) on which a PLLA/
P4HB stent or a 316L stent was implant-
ed was left to chance. Following stent im-
plantation, the balloon catheters were de-
flated and withdrawn. Once implantation 
was complete, layer-by-layer wound clo-
sure was performed.
Antithrombotic medication
The animals received continuous intra-
venous heparin (50 IU/kg per hour) dur-
ing the entire intervention. Oral dual an-
tiplatelet drugs comprising 250 mg ace-
tylsalicylic acid (ASA; Aspirin, Bayer, 
Leverkusen, Germany) and 75 mg clop-
idogrel bisulfate (Plavix; Sanofi-Synthe-
labo, Berlin, Germany) were administered 
daily from postoperative day 3 until the 
end of the experiment.
Investigation methods
Basic parameters (BW, heart rate, arterial 
RR, pO2, pCO2, hemoglobin, hematocrit, 
partial thromboplastin time, C-reactive 
protein) were routinely monitored in all 
animals pre-, intra- and postoperatively.
Invasive intra-arterial angiography 
(digital subtraction angiography, DSA) 
was performed using a high-pressure in-
jector (Medrad, Avida Injector, Germany) 
to assess vessel size before, and vessel re-
action after, stent dilatation.
Contrast-enhanced computed tomog-
raphy (CT) examinations were performed 
on the previously premedicated animals 
at the Radiological Unit of the University 
Medicine Rostock 4 weeks following stent 
implantation to assess stent patency and 
for the purposes of flow measurement.
Statistical analysis
Expansion length as well as stent and ves-
sel diameter were measured from the CT 
data using the Leonardo Workstation 
(Siemens Medical Solution, Erlangen, 
Germany). The distal degree of steno-
sis was calculated according to the North 
American Symptomatic Carotid End-
arterectomy Trial (NASCET), whereby 
the vessel inner diameter in the region of 
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Fig. 1 9 The biodegradable PLLA/P4HB stent unexpanded (top) and expand-
ed (bottom)
 
Fig. 2 8 A PLLA/P4HB stent mounted on a PTA balloon catheter and predi-
lated extracorporeally with 1 bar
 
Fig. 3 8 X-ray showing early dilatation of a 
PLLA/P4HB stent (left) compared with the im-
planted 316L metal stent (right) in situ (porcine 
carotid artery)
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plaque-induced vessel stenosis was sub-
stituted by the stent inner diameter (IDS):
 
(1)
Using statistical methods (SigmaPlot Ver-
sion 12.0), the data were given as a mean 
value ± standard deviation(SD). Differ-
ences between two groups were com-
pared using Student’s t-test for unpaired 
samples. The Friedmann test was used for 
more than two related samples, whilst the 
Kruskal-Wallis one-way analysis of vari-
ance was used for more than two unrelat-
ed samples. A p-value of less than 0.05 was 
considered statistically significant.
Results
All stents could be successfully implant-
ed in the CCA in experimental animals. 
All animals survived until the end of the 
study period. No wound healing dis-
orders were observed during this time. 
The animals exhibited a weight gain of 
12.1 ± 2.3 kg within the 4-week period.
Following successful implantation, all 
stents showed good dilatation and pa-
tency on final angiography. None of the 
stents had collapsed or showed signs of 
relevant recoil. All stents had remained at 
the target site and patent following defla-
tion and withdrawal of the balloon cathe-
ter. . Fig. 3 shows an X-ray demonstrat-
ing early dilatation in a polymer stent 
compared with a metal stent.
At 4 weeks following implantation, 
all carotid stents were open and perme-
able, irrespective of the side of the CCA 
on which stents had been placed. . Fig. 4 
shows representative CT images of the 
CCA fitted with both types of stent in sag-
ittal, coronal and axial planes.
A significantly higher degree of ste-
nosis according to NASCET was seen in 
the CCA in the group with PLLA/P4HB 
stents compared with the metal stent 
group (52.05 ± 5.80 % vs. 35.65 ± 3.72 %; 
p < 0.002) 4 weeks following endovascular 
implantation. The distal degree of steno-
sis in the PLLA/P4HB stent group could 
be reduced to the level of the metal stent 
group by means of oral application of ator-
vastatin (39.81 ± 8.57 % vs. 44.21 % ± 2.34; 
p > 0.234). No differences were seen be-
tween animals receiving and those not 
receiving atorvastatin in the metal stent 
group (p > 0.07). In contrast, in the PLLA/
P4HB stent group, a significantly lower 
degree of distal stenosis was seen in ani-
mals receiving atorvastatin compared with 
those not (p < 0.009) (. Fig. 5).
The vessel lumen distal and proxi-
mal to the stent showed no differences 
between the two stent groups, irrespec-
tive of whether or not the animals had 
received atorvastatin (. Tab. 1). No dif-
ferences between nominal length (316L: 
25 mm; PLLA/P4HB: 20 mm) and ex-
panded length (316L: 25.27 ± 0.80 mm; 
PLLA/P4HB: 19.50 ± 1.13 mm) were ob-
served in either stent group.
Discussion
In this study, biodegradable PLLA/P4HB 
stents were successfully implanted in the 
CCA of domestic swine using an endovas-
NASCET ID ID IDG S G[%] ( ) /= − ⋅100
Abstract · Zusammenfassung
Biodegradable polymeric stents for vascular application 
in a porcine carotid artery model. English version
Abstract
Over the past years the development of bio-
degradable polymeric stents has made great 
progress; nevertheless, essential problems 
must still be solved. Modifications in design 
and chemical composition should optimize 
the quality of biodegradable stents and re-
move the weaknesses. New biodegradable 
poly-L-lactide/poly-4-hydroxybutyrate (PLLA/
P4HB) stents and permanent 316L stents 
were implantedendovascularly into both 
common carotid arteries of 10 domestic pigs. 
At 4 weeks following implantation, comput-
ed tomography (CT) angiography was car-
ried out to identify the distal degree of ste-
nosis. The PLLA/P4HB group showed a con-
siderably lower distal degree of stenosis by 
additional oral application of atorvastatin 
(mean 39.81 ± 8.57 %) compared to the un-
treated PLLA/P4HB group without atorvas-
tatin (mean 52.05 ± 5.80 %). The 316L stents 
showed no differences in the degree of dis-
tal stenosis between the group treated with 
atorvastatin (mean 44.21 ± 2.34 %) and the 
untreated group (mean 35.65 ± 3.72 %). Bio-
degradable PLLA/P4HB stents generally rep-
resent a promising approach to resolving the 
existing problems in the use of permanent 
stents. Restitutio ad integrum is only achiev-
able if a stent is completely degraded.
Keywords
Biodegradable stents · Poly(L-lactide) ·  
Poly(4-hydroxybutyrate) ·  
Common carotid artery · Atorvastatin
Biodegradierbare Polymerstents für die vaskuläre 
Applikation im Karotis-Modell beim Schwein
Zusammenfassung
Obwohl die Entwicklung biodegradierba-
rer Polymerstents in den letzten Jahren gro-
ße Fortschritte gemacht hat, verbleiben ent-
scheidende noch zu lösende Probleme be-
stehen. Veränderungen im Design und in der 
chemischen Zusammensetzung sollen die 
Eigenschaften biodegradierbarer Stents opti-
mieren und ihre Schwächen beseitigen.
Der neue PLLA/P4HB-Stent konnte er-
folgreich endovaskulär in die A. carotis com-
munis von 10 Landschweinen implantiert 
werden, bei vergleichbaren mechanischen Ei-
genschaften zu 316L-Metallstents als Kon-
trollgruppe. 4 Wochen nach Implantation er-
folgte eine Angio-CT zur Stenosegradbestim-
mung. Es zeigten sich deutlich höhere Ste-
nosegrade in der PLLA/P4HB-Stent-Grup-
pe (52,05 ± 5,80 %) gegenüber der Metall-
Stent-Gruppe (35,65 ± 3,72 %). Durch die ora-
le Gabe von Atorvastatin konnte der distale 
Stenosegrad nach NASCET in der PLLA/P4HB-
Stent-Gruppe (39,81 ± 8,57 %) auf das Niveau 
der Metall-Stent-Gruppe (44,21 % ± 2,34) ge-
senkt werden.
Der PLLA/P4HB-Stent stellt einen vielver-
sprechenden Ansatz zur Lösung der beste-
henden Probleme beim Einsatz permanenter 
Stents dar. Nur wenn sich ein Stent vollstän-
dig auflöst, ist eine Heilung im Sinne einer 
Restitutio ad integrum möglich.
Schlüsselwörter
Biodegradierbarer Stent · Poly(L-Lactid) · 
Poly(4-Hydroxybuttersäure) ·  
A. carotis communis · Atorvastatin
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cular approach. It was possible to show 
the functionality of the PLLA/P4HB stent 
by direct comparison with a standard per-
manent 316L BMS.
The advantages of endovascular man-
agement of vascular disease compared 
with open surgery include reduced mor-
tality and a lower complication rate [3]. 
The finality of using permanent stents has 
hitherto represented a problem in inter-
ventional treatment with stent placement. 
Once implanted, they are difficult to re-
move and, in contrast to biodegradable 
stents, make surgical intervention in the 
relevant vessel segment challenging. As 
lifelong foreign bodies, they continuous-
ly cause local immunological irritation in 
the vessel wall and the associated onset of 
in-stent restenosis (ISR) [4]. It is known 
that this causal inflammatory reaction 
and its effect on proliferation processes 
can be reduced by removing the foreign 
body, whereby the use of biodegradable 
stents represents an advantage.
There has been significantly less inves-
tigation into the clinical use of biodegrad-
able stents in the peripheral vascular sys-
tem compared with the current status of 
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Fig. 4 8 Representative CT images of the common carotid artery, fitted with both types of stent, in the sagittal (a, b), coronal 
(d, e) and axial (c, f) planes. c Without contrast medium. e Multiplanar reconstruction. Thin arrows point to a PLLA/P4HB stent, 











































Fig. 5 8 Degree of distal stenosis according to NASCET (%) 4 weeks following endovascular stent 
placement in the common carotid artery. Data are presented as mean value ± SD. The Kruskal-Wallis 
test, followed by the Student-Newman-Keuls test, was used to compare the groups
 
research relating to the coronary vascu-
lature [5]. To date, they have only been 
used in infrapopliteal interventions in the 
peripheral vascular system, since smaller 
stents in this location need to withstand 
less stress [6]. Femoropopliteal arter-
ies (superficial femoral and popliteal ar-
tery), on the other hand, are exposed to 
considerable mechanical stresses such as 
compression, bending and torsion. For 
this reason, there are varying stent frac-
ture rates in vascular segments depending 
on stent design, with the result that biode-
gradable stents have only rarely been used 
in clinical applications in this region [7].
The present study used direct and in-
direct imaging methods to visualize the 
implanted stents. Direct methods permit-
ted visualization of the stents themselves, 
whilst indirect methods demonstrated 
surrounding changes caused by the stent, 
without visualizing the stent itself. The 
permanent metal stents could be visual-
ized, in both dilated and undilated states, 
at all times under X-ray fluoroscopy, 
making it possible to assess them directly 
and at any time. However, it was not pos-
sible to directly visualize the biodegrad-
able polymer stents without X-ray mark-
ers due to lack of X-ray density during im-
plantation. Only by inflating the balloon 
catheter with contrast medium was it pos-
sible to indirectly observe deployment 
behaviour. In this regard, biodegradable 
polymer stents rely on the use of X-ray 
markers, e.g. gold (Igaki-Tamai stent) [8] 
or platinum (bioresorbable vascular scaf-
fold stent) [9]. Due to poor differentia-
bility between polymer and vessel wall, it 
was not possible to measure the outer di-
ameter of the PLLA/P4HB stents or stent-
ed vessels during contrast-enhanced CT. 
However, it was possible to define the in-
ner diameter from the contrast medium 
column, and thus determine the distal 
degree of stenosis according to the NA-
SCET definition [10]. The inner diameter 
of stent-induced stenosis in the distal (and 
proximal) vessels was comparable in this 
study, making the two stent groups equal 
in terms of distal degree of stenosis. At the 
same time, it should also be borne in mind 
that stent inner diameter was used to cal-
culate the degree of stenosis, whereby the 
wall thickness of the PLLA/P4HB stents 
is proportionally 1.5 times greater com-
pared with the 316L stents (316L: 160 μm 
vs. PLLA/P4HB: 250 μm).
The present study showed a signifi-
cantly lower degree of distal stenosis in 
animals treated with oral atorvastatin 
compared with untreated animals in the 
PLLA/P4HB group at contrast-enhanced 
CT 4 weeks following implantation. Ator-
vastatin treatment was able to reduce the 
distal degree of stenosis in the PLLA/
P4HB stent group to that of the metal 
stent group. Given the high prevalence 
and incidence of cardiovascular disease, 
statins play an important role in clinical 
routine. In addition to their main action, 
low-density lipoprotein (LDL) cholester-
ol reduction, statins also stabilize plaque 
[11] and demonstrably reduce restenosis 
rates [12]. In an animal study, statin-elut-
ing stents were shown to have a signifi-
cant effect on neointimal hyperplasia in 
stented coronary vessels in a swine model. 
An initial clinical study, however, showed 
statin-eluting stents to cause higher than 
expected neointimal proliferation [14]. 
According to the results of this study, 
biodegradable statin-eluting stents repre-
sent a promising opportunity in terms of 
further experimental investigations to in-
crease drug concentrations at the implan-
tation site and further minimize adverse 
side effects.
All experimental animals received dual 
oral anticoagulation with ASA and clopi-
dogrel prior to surgery. The literature re-
ports that this approach resulted in a re-
duction in occlusion rates in percutaneous 
transluminal coronary angioplasty (PT-
CA) with BMS [15], leading to dual anti-
platelet therapy becoming established as 
the standard procedure in coronary inter-
ventions with stents [15]. Although stud-
ies to assess anticoagulation in stent im-
plantation in the peripheral vasculature 
are scant, they suggest success similar to 
that seen in the coronary system [16]. In-
deed, our model also showed no occlu-
sion in stented vessels at 4 weeks under 
this form of dual anticoagulation therapy, 
as did earlier experiments conducted by 
our working group [17, 18].
To date, the polymeric stent used here 
is not sterilized, but rather only disinfect-
ed according to the study by Tamai et al. 
[8]. Various sterilization procedures can 
have a critical effect on the mechanical 
properties of the stent. Grabow et al. [19] 
discovered that sterilization methods us-
ing beta and gamma radiation cause a 
marked reduction in molecular weight 
and mechanical properties, while increas-
ing crystallinity.
No specially designed balloon cath-
eters to dilate the biodegradable PLLA/
P4HB stents were available for the pur-
poses of this study, whereas the 316L stents 
were available as commercial stent-bal-
loon catheter systems. Therefore, balloon 
catheters for PLLA/P4HB stent implan-
tation needed to be predilated extracor-
poreally after the stents had been mount-
ed. Despite the demonstrated feasibility 
of advancing the predilated balloon cath-
eter over an 8-F sheath with a rotating he-
mostasis valve for manual rotation (Tuo-
hy-Borst) without removing the mounted 
stent, the development of a dedicated stent 
delivery system would make predilatation 
obsolete and contribute significantly to re-
ducing the sheath diameter required.
Limitations
All materials used for stent implantation 
were used in the same way as in humans. 
This is possible due to the comparable 
anatomical proportions and physiology 
of the cardiovascular system in humans 
and swine [20]. A limitation of the study 
lies in the fact that stents were implant-
ed in healthy, non-arteriosclerotic vessels; 
therefore, it is possible that the conclu-
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Table 1 Luminal patency of the vessel at the distal and proximal ends of the stent (inner 
vessel diameter, IDvessel). Data are presented as mean value±SD. The Kruskal-Wallis test was 
used to compare groups









Distal 5.20 ± 0.35 5.42 ± 0.38 5.38 ± 0.63 5.60 ± 0.52 0.638
Proximal 5.22 ± 0.38 5.22 ± 0.72 4.74 ± 0.45 4.86 ± 0.25 0.302
sions drawn here are only valid under the 
conditions presented.
Conclusion
 5 The new biodegradable PLLA/P4HB 
stent demonstrated that it can be 
used in endovascular applications 
and that it is suitable for long-term 
testing in the established porcine 
model.
 5 The future incorporation of biologi-
cally active substances aimed at sup-
pressing neointimal hyperplasia 
could further reduce restenosis rates.
 5 Overall, the PLLA/P4HB stent repre-
sents a promising approach to solving 
existing problems in the use of per-
manent stents. Restitutio ad integrum 
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